446064-65-9

Upstream product

• 446064-64-8 (E)-(S)-4-tert-Butoxycarbonylamino-5-(4-triisopropylsilanyloxy-phenyl)-pent-2-enoic acid allyl ester 
• 735327-63-6 (S)-methyl 2-(tert-butoxycarbonylamino)-3-(4-(triisopropylsilyloxy)phenyl)propanoate 
• 151133-13-0 [(S)-1-Formyl-2-(4-triisopropylsilanyloxy-phenyl)-ethyl]-carbamic acid tert-butyl ester 
• 104127-76-6 allyl (triphenylphosphoranylidene)acetate 
• 13139-16-7 N-tert-butoxycarbonyl-D-alloisoleucine 

Downstream Products

• 446064-67-1 C₆₈H₉₄Cl₃N₉O₁₆Si 
• 446064-72-8 C₆₅H₉₀Cl₃N₉O₁₆Si 
• 475503-59-4 C₇₁H₁₀₅N₉O₁₆Si₂ 
• 446064-66-0 (E)-(S)-4-((2R,3S)-2-Amino-3-methyl-pentanoylamino)-5-(4-triisopropylsilanyloxy-phenyl)-pent-2-enoic acid allyl ester 

Relevant academic research and scientific papers

Application of cyano ylide methodology to the synthesis of cyclotheonamides E2 and E3

A total synthesis of cyclotheonamides E2 and E3 is reported. A key step in the synthesis involves the formation of the α-keto amide linkage by application of the cyano ylide activation of a carboxyl group as developed in our earlier syntheses of cyclic peptide protease inhibitors.

Total synthesis of cyclotheonamides E2 and E3: Application of cyano ylide methodology

A total synthesis of cyclotheonamides E2 and E3 is reported. A key step in the synthesis involves the formation of the α-keto amide linkage by application of the cyano ylide activation of a carboxyl group as developed in our earlier syntheses of cyclic peptides in the family of protease inhibitors.